相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Nutritional status and symptom burden in advanced non-small cell lung cancer: results of the dietetic assessment and intervention in lung cancer (DAIL) trial
Iain Phillips et al.
BMJ SUPPORTIVE & PALLIATIVE CARE (2021)
Prognostic value of baseline and change in neutrophil-to-lymphocyte ratio for survival in advanced non-small cell lung cancer patients with poor performance status receiving PD-1 inhibitors
Shixue Chen et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2021)
Prognostic Nutritional Index identifies risk of early progression and survival outcomes in Advanced Non-small Cell Lung Cancer patients treated with PD-1 inhibitors
Na Liu et al.
JOURNAL OF CANCER (2021)
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
S. S. Ramalingam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Relationship between markers of malnutrition and clinical outcomes in older adults with cancer: systematic review, narrative synthesis and meta-analysis
Alex F. Bullock et al.
EUROPEAN JOURNAL OF CLINICAL NUTRITION (2020)
Management of Cancer Cachexia: ASCO Guideline
Eric J. Roeland et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
The impact of immune-inflammation-nutritional parameters on the prognosis of non-small cell lung cancer patients treated with atezolizumab
Taichi Matsubara et al.
JOURNAL OF THORACIC DISEASE (2020)
Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial
Gary Middleton et al.
LANCET RESPIRATORY MEDICINE (2020)
Peripheral Blood Biomarkers Associated With Outcome in Non-small Cell Lung Cancer Patients Treated With Nivolumab and Durvalumab Monotherapy
Meilin Jiang et al.
FRONTIERS IN ONCOLOGY (2020)
Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs)
Ye Li et al.
FRONTIERS IN ONCOLOGY (2020)
Association of the neutrophil to lymphocyte ratio and clinical outcomes in patients with lung cancer receiving immunotherapy: a meta-analysis
Jing Jin et al.
BMJ OPEN (2020)
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC
Roy S. Herbst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Optimising patient fitness: strategies to reduce the effects of cancer cachexia in patients with advanced lung cancer
Iain Phillips et al.
CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE (2020)
A biobank analysis of prognostic biomarkers of the systemic inflammatory response in patients presenting with malignancy of undefined primary origin
M. Stares et al.
EUROPEAN JOURNAL OF CANCER (2020)
Pretreatment nutritional status and response to checkpoint inhibitors in lung cancer
Chung-Shien Lee et al.
LUNG CANCER MANAGEMENT (2020)
Advances in Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer Based on Accurate Molecular Typing
Jingsi Dong et al.
FRONTIERS IN PHARMACOLOGY (2019)
Combined exercise and nutritional rehabilitation in outpatients with incurable cancer: a systematic review
Charlie C. Hall et al.
SUPPORTIVE CARE IN CANCER (2019)
Prognostic role of pretreatment neutrophil-to-lymphocyte ratio in non-small cell lung cancer patients treated with systemic therapy: a meta-analysis
Zimu Wang et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2019)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Anti-cytokines in the treatment of cancer cachexia
Bernard Lobato Prado et al.
ANNALS OF PALLIATIVE MEDICINE (2019)
The emerging treatment landscape of targeted therapy in non-small-cell lung cancer
Min Yuan et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
L. Paz-Ares et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Prognostic value of prognostic nutritional index in lung cancer: a meta-analysis
Dan Li et al.
JOURNAL OF THORACIC DISEASE (2018)
Cancer cachexia: rationale for the MENAC (Multimodal-Exercise, Nutrition and Anti-inflammatory medication for Cachexia) trial
Tora S. Solheim et al.
BMJ SUPPORTIVE & PALLIATIVE CARE (2018)
Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer A Meta-Analysis
Chee Khoon Lee et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
Justin F. Gainor et al.
CLINICAL CANCER RESEARCH (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials
Jennifer S. Temel et al.
LANCET ONCOLOGY (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Malnutrition: laboratory markers vs nutritional assessment
Shishira Bharadwaj et al.
GASTROENTEROLOGY REPORT (2016)
Serum albumin is a strong predictor of survival in patients with advanced-stage non-small cell lung cancer treated with erlotinib
O. Fiala et al.
NEOPLASMA (2016)
Effects of rehabilitation among patients with advances cancer: a systematic review
Minna R. J. Salakari et al.
ACTA ONCOLOGICA (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Albumin and Neutrophil Combined Prognostic Grade as a New Prognostic Factor in Non-Small Cell Lung Cancer: Results from a Large Consecutive Cohort
Haifeng Sun et al.
PLOS ONE (2015)
The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancer
Donald C. McMillan
CANCER TREATMENT REVIEWS (2013)
Prognostic Factors in Patients with Advanced Cancer: A Comparison of Clinicopathological Factors and the Development of an Inflammation-Based Prognostic System
Barry J. Laird et al.
CLINICAL CANCER RESEARCH (2013)
Prognostic impact of serum albumin levels on the recurrence of stage I non-small cell lung cancer
Ying Jin et al.
CLINICS (2013)
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Definition and classification of cancer cachexia: an international consensus
Kenneth Fearon et al.
LANCET ONCOLOGY (2011)
Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literature
Digant Gupta et al.
NUTRITION JOURNAL (2010)
Serum albumin: Relationship to inflammation and nutrition
BR Don et al.
SEMINARS IN DIALYSIS (2004)
分享论文
